Clinical and Investigative Medicine最新文献_第10页

Efficacy Of Pegylated Liposomal Doxorubicin-based Neoadjuvant Chemotherapy In Breast Cancer: A Single Center Experience. 聚乙二醇脂质体以阿霉素为基础的乳腺癌新辅助化疗的疗效:单中心经验。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2021-03-21 DOI: 10.25011/CIM.V44I1.35196

I. Tsai, Chih-Chiang Hung

{"title":"Efficacy Of Pegylated Liposomal Doxorubicin-based Neoadjuvant Chemotherapy In Breast Cancer: A Single Center Experience.","authors":"I. Tsai, Chih-Chiang Hung","doi":"10.25011/CIM.V44I1.35196","DOIUrl":"https://doi.org/10.25011/CIM.V44I1.35196","url":null,"abstract":"PURPOSE\u0000Neoadjuvant chemotherapy using a doxorubicin-based regimen has recently become a common therapeutic option for operable breast cancer. This study aimed to investigate the efficacy of polyethylene glycol-coated liposomal doxorubicin (PLD)-based chemotherapy for breast cancer in neoadjuvant settings.\u0000\u0000\u0000METHODS\u0000A total of 227 female operable breast cancer patients who were diagnosed between January 2009 and December 2017 and completed neoadjuvant PLD-based chemotherapy were retrospectively included. The logistic regression analysis was used to determine the associations between pathologic complete response (pCR) and preoperative clinicopathological characteristics. The breast cancer recurrence rate was estimated using the survival analysis.\u0000\u0000\u0000RESULTS\u0000A higher pCR rate was found in the patients with clinically negative lymph nodes and HER2-enriched patients. Moreover, the patients who achieved pCR also had a better prognosis outcome. A recurrence rate of 11.5% (n=26) was observed during a median follow-up of 11.63 months, and the recurrence rate of the pCR group (2.04%; 95% CI = 0.29-13.62) was lower than the non-pCR group (14.62%; 95% CI = 10.12-20.87). Higher histological grade was also associated high pCR rate (52.0% vs 40.0%).\u0000\u0000\u0000CONCLUSION\u0000The use of PLD-containing chemotherapeutics in neoadjuvant settings might have benefits for non-metastatic operable breast cancer in Taiwanese females.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2021-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74935606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A Novel Sirolimus-eluting Biodegradable Magnesium-based Alloy Scaffold: Six-month Results In Porcine Peripheral Arteries. 一种新型西罗莫司洗脱型可生物降解镁基合金支架:在猪外周动脉中的六个月效果。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2021-03-21 DOI: 10.25011/cim.v44i1.35292

Xin-Nong Liu, Cheng-Jia Qu, Yong-Bao Zhang, Jie Fang, Le-Qun Teng, Xiang-Yu Zhang, Chen-Yang Shen

{"title":"A Novel Sirolimus-eluting Biodegradable Magnesium-based Alloy Scaffold: Six-month Results In Porcine Peripheral Arteries.","authors":"Xin-Nong Liu, Cheng-Jia Qu, Yong-Bao Zhang, Jie Fang, Le-Qun Teng, Xiang-Yu Zhang, Chen-Yang Shen","doi":"10.25011/cim.v44i1.35292","DOIUrl":"https://doi.org/10.25011/cim.v44i1.35292","url":null,"abstract":"Purpose: Magnesium-based alloy scaffold is a promising biodegradable stent due to its intrinsic mechanical performance and biocompatibility. Based on our preliminary experiments, we designed a novel sirolimus-eluting magnesium-based alloy scaffold. This work aimed to assess its safety and degradation performance in vivo.Methods: The scaffolds were implanted in the lower limb arteries of Bama mini-pigs. Safety was defined as no immediate thrombosis or >30% residual stenosis, which was assessed with optical coherence tomography and digital subtraction angiography. Blood biochemical analyses were performed to evaluate hepatorenal toxicity. The degradation process of the scaffolds, the endothelialization, and lumen loss of the stented-vessels were detected with scanning electron microscopy, immunohistochemical, hematoxylin-eosin staining and optical coherence tomography.Results: Twenty-four scaffolds were successfully implanted in six pigs with no signs of immediate thrombosis or >30% residual stenosis. The scaffolds were covered by endothelium at one month and absolutely resorbed at six months post implantation. Blood analysis showed that the hepatorenal function except for alanine aminotransferase and γ-glutamyl transpeptidase was normal. Obvious intimal hyperplasia and lumen loss were found in the stented vessels at three months, while the diameters and inner lumen areas of stented segments had increased significantly at six months (p.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2021-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25497951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The Covid-19 Pandemic Has Exposed Opportunities To Strengthen Our Health Research Systems. Covid-19大流行为加强我们的卫生研究系统提供了机会。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2021-03-21 DOI: 10.25011/cim.v44i1.36029

Bev J Holmes, Alex MacKenzie, Bruce McManus, Aubie Angel Angel

引用次数: 0

International training considerations of Canadian Clinician-Scientist Trainees - A national survey. 加拿大临床科学家实习生的国际培训考虑-一项全国性调查。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2020-12-27 DOI: 10.25011/cim.v43i4.35003

Adam Pietrobon, Elina K Cook, Charles Yin, Derek C H Chan, Tina B Marvasti

{"title":"International training considerations of Canadian Clinician-Scientist Trainees - A national survey.","authors":"Adam Pietrobon, Elina K Cook, Charles Yin, Derek C H Chan, Tina B Marvasti","doi":"10.25011/cim.v43i4.35003","DOIUrl":"https://doi.org/10.25011/cim.v43i4.35003","url":null,"abstract":"Purpose: Canadian clinician-scientist trainees enrolled in dual degree programs often pursue an extended training route following completion of MD and MSc or PhD degrees. However, the proportion, plans and reasoning of trainees who intend to pursue training internationally following dual degree completion has not been investigated. In this study, we assessed the international training considerations of current clinician-scientist trainees.Methods: We designed an 11-question survey, which was sent out by program directors to all current MDPhD program and Clinician Investigator Program (CIP) trainees. Responses were collected from July 8, 2019 to August 8, 2019.Results: We received a total of 191 responses, with representation from every Canadian medical school and both MD-PhD program and CIP trainees. The majority of trainees are considering completing additional training outside Canada, most commonly post-doctoral and/or clinical fellowships. The most common reasons for considering international training include those related to quality and prestige of training programs. In contrast, the most common reasons for considering staying in Canada for additional training are related to personal and ethical reasons. Irrespective of intentions to pursue international training, the majority of trainees ultimately intend to establish a career in Canada.Conclusion: While most trainees are considering additional training outside of Canada due to prestige and quality of training, the majority of trainees intend to pursue a career as a clinician-scientist back in Canada. Trainees would likely benefit from improved guidance and mentorship on the value of international training, as well as enhanced support in facilitating cross-border mobility.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39105625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Long non-coding RNA TUSC7 suppressed colorectal cancer progression via regulation of miR-23b/PDE7A Axis. 长链非编码RNA TUSC7通过调控miR-23b/PDE7A轴抑制结直肠癌的进展。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2020-12-27 DOI: 10.25011/cim.v43i4.34703

Lingfang Hao, Yaofeng Yun, Run Liang, Gang Yuan

{"title":"Long non-coding RNA TUSC7 suppressed colorectal cancer progression via regulation of miR-23b/PDE7A Axis.","authors":"Lingfang Hao, Yaofeng Yun, Run Liang, Gang Yuan","doi":"10.25011/cim.v43i4.34703","DOIUrl":"https://doi.org/10.25011/cim.v43i4.34703","url":null,"abstract":"Purpose: Despite advances in our understanding of the roles of the long noncoding RNA (lncRNA) tumor suppressor candidate 7 (TUSC7) in cancer biology, which has been identified to act as a tumor suppressor by regulating cell proliferation, apoptosis, migration, invasion, cell cycle and tumor growth, its function in colorectal cancer remains unknown.Methods: The expression levels of TUSC7 in colorectal cancer tissues and cell lines were determined, and the biological functions of TUSC7 to cancer progression in colorectal cancer were investigated via correlation analysis of clinical samples, cell viability assay, transwell assay and apoptosis analysis. Further, the molecular regulatory mechanisms of TUSC7 were demonstrated by luciferase reporter assay and western blotting.Results: We observed that the expression of TUSC7 was markedly decreased in colorectal cancer cell lines. Moreover, the lower expression of TUSC7 was correlated with advanced clinical grades and poorer survival and may be an independent risk factor for colorectal cancer. Moreover, the expression of TUSC7 inhibited cell proliferation, invasion and epithelial-to-mesenchymal transition (EMT), while it facilitated apoptosis through competitively binding miR-23b. We also found that TUSC7 decreased the expression of phosphodiesterase 7A (PDE7A), a downstream target of miR-23b, through the TUSC7/miR-23b/PDE7A axis.Conclusion: We demonstrated the expression of TUSC7 suppressed colorectal cancer progression through the TUSC7/miR-23b/PDE7A axis, suggesting that TUSC is a potential target for therapeutic intervention in colorectal cancer.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38757042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

MiR-34c regulates the proliferation and apoptosis of lung cancer cells. MiR-34c调控肺癌细胞的增殖和凋亡。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2020-12-27 DOI: 10.25011/cim.v43i4.34997

Xianliang Jiang, Ming Li, Li Ke

{"title":"MiR-34c regulates the proliferation and apoptosis of lung cancer cells.","authors":"Xianliang Jiang, Ming Li, Li Ke","doi":"10.25011/cim.v43i4.34997","DOIUrl":"https://doi.org/10.25011/cim.v43i4.34997","url":null,"abstract":"Purpose: As miR-34c acts as a tumor suppressant for multiple cancers, the purpose of this study was to investigate that role that miR-34c plays in the proliferation and apoptosis of lung cancer.Methods: The expression of miR-34c in 600 patients with lung cancer was quantitatively analyzed with real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) technology and correlated to clinical pathological parameters. The CCK-8 analysis and flow cytometry were carried out to detect cell proliferation and apoptosis in miR-34c-mimic transfected cell lines. Moreover, the regulation of miR-34c to interleukin-6 (IL-6) in cell lines was detected by western blot, qRT-PCR and dual-luciferase reporter assay.Results: The expression of miR-34c was downregulated in lung cancer compared with adjacent normal tissues. The expression level of miR-34c was linked to stromal invasion. Furthermore, overexpressing miR-34c played an active role in effectively inhibiting cell proliferation and inducing apoptosis. In addition, a significant inverse relationship was exhibited between the expression of miR-34c and IL-6 in tumor tissues.Conclusion: At the molecular level, IL-6 can be used as a direct target of miR-34c in the treatment of lung cancer cells and miR-34c can be used as an effective biomarker and therapeutic target for lung cancer.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38757044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Ticagrelor alleviates sepsis-induced myocardial injury via an adenosine-dependent pathway in a mouse sepsis model. 替格瑞洛在小鼠脓毒症模型中通过腺苷依赖途径减轻脓毒症诱导的心肌损伤。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2020-12-27 DOI: 10.25011/cim.v43i4.34775

Shengxing Tang, Cong Fu, Qiancheng Xu, Wenjun Guo, Yuhan Cao

{"title":"Ticagrelor alleviates sepsis-induced myocardial injury via an adenosine-dependent pathway in a mouse sepsis model.","authors":"Shengxing Tang, Cong Fu, Qiancheng Xu, Wenjun Guo, Yuhan Cao","doi":"10.25011/cim.v43i4.34775","DOIUrl":"https://doi.org/10.25011/cim.v43i4.34775","url":null,"abstract":"Purpose: The purpose of this study was to determine whether ticagrelor, a classic anti-platelet drug, has a therapeutic effect on sepsis-induced myocardial injury.Methods: The C57BL6J mice received oral ticagrelor (10, 25 and 50 mg/kg) for seven days after which cecum ligation and puncture (CLP) were performed. An adenosine-receptor antagonist (CGS15943) was administered two hours before CLP. After 24 h, cardiac function was measured using cardiac echocardiography, then the heart and blood were collected. Hematoxylin and eosin (HE) staining and terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL staining) were used to observe pathological changes and cardiomyocyte apoptosis. Plasma concentration of TNF-α, IL-6 and adenosine and myocardial tissue levels of TNF-α and IL-6 were determined. Survival analysis was performed. Western blot was used to determine the expression of a signalling protein in the myocardial tissue.Results: The HE and TUNEL staining showed less inflammatory cell infiltration and less cardiomyocyte apoptosis in the ticagrelor group. Cardiac echocardiography showed preserved heart function in the ticagrelor group. Plasma TNF-α, IL-6 and relative expression of TNF-α and IL-6 in myocardial tissue were significantly lower in the ticagrelor group. Plasma adenosine levels were significantly higher in the ticagrelor group. Adenosine-receptor antagonists significantly blocked the protective effect of ticagrelor. Ticagrelor reduced the mortality of sepsis mice, and this reduction was blocked by the adenosine-receptor antagonist. Western blot showed that ticagrelor activated the phosphorylation of AKT and mTOR. Adenosine-receptor antagonists inhibited the activation of AKT and mTOR.Conclusion: The protective effect of ticagrelor was dependent on adenosine-receptor activation, with downstream upregulation of phosphorylation of AKT and mTOR.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38757043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Association between APE1 ASP148GLU and colorectal cancer risk: A meta-analysis. APE1 ASP148GLU与结直肠癌风险的关系:一项荟萃分析

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2020-12-27 DOI: 10.25011/cim.v43i4.34987

Caizhao Lin, Yuewei Jin, Shaobing Cheng, Weibing Wang

{"title":"Association between APE1 ASP148GLU and colorectal cancer risk: A meta-analysis.","authors":"Caizhao Lin, Yuewei Jin, Shaobing Cheng, Weibing Wang","doi":"10.25011/cim.v43i4.34987","DOIUrl":"https://doi.org/10.25011/cim.v43i4.34987","url":null,"abstract":"Background: Colorectal cancer (CRC) is recognized as one of the most common cancer globally. The association between CRC and apurinic endonuclease 1 (APE1) Asp148Glu polymorphism remains unclear; thus, this meta-analysis aimed to explore whether APE1 Asp148Glu polymorphism is related to CRC risk.Methods: Embase, PubMed, Cochrane library, CNKI and Wanfang databases were subject to a systematic search until April, 17, 2020 to evaluate the effect of APE1 Asp148Glu polymorphism on CRC risk. The associated strength was used to evaluate with odds ratios (ORs) with 95% confidence intervals (CIs) between Asp148Glu polymorphism and CRC risk. Subgroup analyses were also performed.Results: In total, 11 articles including 8,136 subjects (3,836 cases and 4,300 controls) were included. Five genetic models were analyzed, including the additive model (G vs. T), the heterozygote comparison (TG vs. TT), the homozygote comparison (GG vs. TT), the dominant model (TG+GG vs. TT), and the recessive model (GG vs. TG+TT). In these models, T refers to thymine and G refers to guanine. The APE1 Asp148Glu polymorphism in heterozygote comparison [OR (95%CI) = 1.36 (1.05, 1.75), P=0.019] and dominant model [OR (95%CI) =1.31 (1.07, 1.61), P=0.010] significantly increased CRC risk. No significant association was seen for the additive model [OR (95%CI) = 1.14 (1.00, 1.31), P=0.057], recessive model [OR (95%CI) = 0.97 (0.71, 1.31), P=0.826] or in homozygote comparison [OR (95%CI) = 1.15 (0.88, 1.52), P=0.309]. Moreover, CRC risk indicated a remarkable association with APE1 Asp148Glu polymorphism in the PCR-RFLP additive model, homozygote comparison and recessive model (PG) may be a potential risk factor for CRC.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38757041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effect of melatonin on regeneration of cortical neurons in rats with traumatic brain injury. 褪黑素对创伤性脑损伤大鼠皮质神经元再生的影响。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2020-12-27 DOI: 10.25011/cim.v43i4.34829

Jianbin Ge, Dandan Chen, Jingjing Ben, Xinjian Song, Linqing Zou, Xin Yi

引用次数: 3

Statin use and the overall survival of renal cell carcinoma: A meta-analysis. 他汀类药物的使用和肾细胞癌的总生存率:一项荟萃分析。

IF 0.8 4区医学

Clinical and Investigative Medicine Pub Date : 2020-12-27 DOI: 10.25011/cim.v43i4.34908

Ping Wu, Tingting Xiang, Jing Wang, Run Lv, Yimeng Zhuang, Guangzhen Wu

{"title":"Statin use and the overall survival of renal cell carcinoma: A meta-analysis.","authors":"Ping Wu, Tingting Xiang, Jing Wang, Run Lv, Yimeng Zhuang, Guangzhen Wu","doi":"10.25011/cim.v43i4.34908","DOIUrl":"https://doi.org/10.25011/cim.v43i4.34908","url":null,"abstract":"Purpose: Statins are commonly prescribed drugs that reduce cholesterol levels and the risk of cardiovascular and cerebrovascular events. Clinical studies have shown that statins also possess cancer-preventive properties. Two studies have reported that statins also possess cancer-preventive properties; however, whether statins improve the prognosis of patients with renal cell carcinoma is still unclear. In this study, we used meta-analysis to evaluate the association between statin use and overall survival risk in patients with renal cell carcinoma.Methods: Published studies on statin-treated renal cell carcinoma were retrieved from PubMed, Embase, The Cochrane Library, China National Knowledge Infrastructure and Wanfang databases from inception to July 2019. The relevant data were extracted and a meta-analysis was performed using Cochrane Review Manager (RevMan 5.3) software.Results: Data from five studies, which reported on 5,299 patients, were analysed. The application of statins showed no effects on the overall survival of patients with renal cell carcinoma compared with the control group (OR = 1.07, 95% CI:0.77 to 1.49, P = 0.68).Conclusions: The findings of this meta-analysis suggest that statin application does not affect the overall survival of patients with renal cell carcinoma.","PeriodicalId":50683,"journal":{"name":"Clinical and Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2020-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39105627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7